Direct inhibition of arginase attenuated airway allergic reactions and inflammation in a Dermatophagoides farinae-induced NC/Nga mouse model

Noriko Takahashi, Keiki Ogino, Kei Takemoto, Seiji Hamanishi, Da Hong Wang, Tomoko Takigawa, Masafumi Shibamori, Hironobu Ishiyama, Yoshihisa Fujikura

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The expression of arginase I has been a focus of research into the pathogenesis of experimental asthma, because arginase deprives nitric oxide synthase (NOS) of arginine and therefore participates in the attenuation of bronchodilators such as nitric oxide (NO). The present study used an intranasal mite-induced NC/Nga mouse model of asthma to investigate the contribution of arginase to the asthma pathogenesis, using an arginase inhibitor, N ω-hydroxy-nor-L-arginine (nor-NOHA). The treatment with nor-NOHA inhibited the increase in airway hyperresponsiveness (AHR) and the number of eosinophils in bronchoalveolar lavage fluid. NOx levels in the lung were elevated despite suppressed NOS2 mRNA expression. Accompanied by the attenuated activity of arginase, the expression of arginase I at both the mRNA and protein level was downregulated. The levels of mRNA for T helper 2 cytokines such as IL-4, IL-5, and IL-13, and for chemotactants such as eotaxin-1 and eotaxin-2, were reduced. Moreover, the accumulation of inflammatory cells and the ratio of goblet cells in the bronchiole were decreased. The study concluded that the depletion of NO caused by arginase contributes to AHR and inflammation, and direct administration of an arginase inhibitor to the airway may be beneficial and could be of use in treating asthma due to its anti-inflammatory and airway-relaxing effects, although it is not clear whether the anti-inflammatory effect is direct or indirect.

Original languageEnglish
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume299
Issue number1
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Dermatophagoides farinae
Arginase
Hypersensitivity
Inflammation
Asthma
Messenger RNA
Arginine
Chemokine CCL24
Nitric Oxide
Chemokine CCL11
Anti-Inflammatory Agents
Bronchioles
Goblet Cells
Interleukin-13
Mites
Bronchodilator Agents
Interleukin-5
Bronchoalveolar Lavage Fluid
Eosinophils
Nitric Oxide Synthase

Keywords

  • Arginase inhibitor
  • Experimental asthma
  • nor-NOHA

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology
  • Physiology

Cite this

Direct inhibition of arginase attenuated airway allergic reactions and inflammation in a Dermatophagoides farinae-induced NC/Nga mouse model. / Takahashi, Noriko; Ogino, Keiki; Takemoto, Kei; Hamanishi, Seiji; Wang, Da Hong; Takigawa, Tomoko; Shibamori, Masafumi; Ishiyama, Hironobu; Fujikura, Yoshihisa.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 299, No. 1, 07.2010.

Research output: Contribution to journalArticle

Takahashi, Noriko ; Ogino, Keiki ; Takemoto, Kei ; Hamanishi, Seiji ; Wang, Da Hong ; Takigawa, Tomoko ; Shibamori, Masafumi ; Ishiyama, Hironobu ; Fujikura, Yoshihisa. / Direct inhibition of arginase attenuated airway allergic reactions and inflammation in a Dermatophagoides farinae-induced NC/Nga mouse model. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2010 ; Vol. 299, No. 1.
@article{86fdad649eec4a60b96b280bc0a1cd82,
title = "Direct inhibition of arginase attenuated airway allergic reactions and inflammation in a Dermatophagoides farinae-induced NC/Nga mouse model",
abstract = "The expression of arginase I has been a focus of research into the pathogenesis of experimental asthma, because arginase deprives nitric oxide synthase (NOS) of arginine and therefore participates in the attenuation of bronchodilators such as nitric oxide (NO). The present study used an intranasal mite-induced NC/Nga mouse model of asthma to investigate the contribution of arginase to the asthma pathogenesis, using an arginase inhibitor, N ω-hydroxy-nor-L-arginine (nor-NOHA). The treatment with nor-NOHA inhibited the increase in airway hyperresponsiveness (AHR) and the number of eosinophils in bronchoalveolar lavage fluid. NOx levels in the lung were elevated despite suppressed NOS2 mRNA expression. Accompanied by the attenuated activity of arginase, the expression of arginase I at both the mRNA and protein level was downregulated. The levels of mRNA for T helper 2 cytokines such as IL-4, IL-5, and IL-13, and for chemotactants such as eotaxin-1 and eotaxin-2, were reduced. Moreover, the accumulation of inflammatory cells and the ratio of goblet cells in the bronchiole were decreased. The study concluded that the depletion of NO caused by arginase contributes to AHR and inflammation, and direct administration of an arginase inhibitor to the airway may be beneficial and could be of use in treating asthma due to its anti-inflammatory and airway-relaxing effects, although it is not clear whether the anti-inflammatory effect is direct or indirect.",
keywords = "Arginase inhibitor, Experimental asthma, nor-NOHA",
author = "Noriko Takahashi and Keiki Ogino and Kei Takemoto and Seiji Hamanishi and Wang, {Da Hong} and Tomoko Takigawa and Masafumi Shibamori and Hironobu Ishiyama and Yoshihisa Fujikura",
year = "2010",
month = "7",
doi = "10.1152/ajplung.00216.2009",
language = "English",
volume = "299",
journal = "American Journal of Physiology - Lung Cellular and Molecular Physiology",
issn = "1040-0605",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Direct inhibition of arginase attenuated airway allergic reactions and inflammation in a Dermatophagoides farinae-induced NC/Nga mouse model

AU - Takahashi, Noriko

AU - Ogino, Keiki

AU - Takemoto, Kei

AU - Hamanishi, Seiji

AU - Wang, Da Hong

AU - Takigawa, Tomoko

AU - Shibamori, Masafumi

AU - Ishiyama, Hironobu

AU - Fujikura, Yoshihisa

PY - 2010/7

Y1 - 2010/7

N2 - The expression of arginase I has been a focus of research into the pathogenesis of experimental asthma, because arginase deprives nitric oxide synthase (NOS) of arginine and therefore participates in the attenuation of bronchodilators such as nitric oxide (NO). The present study used an intranasal mite-induced NC/Nga mouse model of asthma to investigate the contribution of arginase to the asthma pathogenesis, using an arginase inhibitor, N ω-hydroxy-nor-L-arginine (nor-NOHA). The treatment with nor-NOHA inhibited the increase in airway hyperresponsiveness (AHR) and the number of eosinophils in bronchoalveolar lavage fluid. NOx levels in the lung were elevated despite suppressed NOS2 mRNA expression. Accompanied by the attenuated activity of arginase, the expression of arginase I at both the mRNA and protein level was downregulated. The levels of mRNA for T helper 2 cytokines such as IL-4, IL-5, and IL-13, and for chemotactants such as eotaxin-1 and eotaxin-2, were reduced. Moreover, the accumulation of inflammatory cells and the ratio of goblet cells in the bronchiole were decreased. The study concluded that the depletion of NO caused by arginase contributes to AHR and inflammation, and direct administration of an arginase inhibitor to the airway may be beneficial and could be of use in treating asthma due to its anti-inflammatory and airway-relaxing effects, although it is not clear whether the anti-inflammatory effect is direct or indirect.

AB - The expression of arginase I has been a focus of research into the pathogenesis of experimental asthma, because arginase deprives nitric oxide synthase (NOS) of arginine and therefore participates in the attenuation of bronchodilators such as nitric oxide (NO). The present study used an intranasal mite-induced NC/Nga mouse model of asthma to investigate the contribution of arginase to the asthma pathogenesis, using an arginase inhibitor, N ω-hydroxy-nor-L-arginine (nor-NOHA). The treatment with nor-NOHA inhibited the increase in airway hyperresponsiveness (AHR) and the number of eosinophils in bronchoalveolar lavage fluid. NOx levels in the lung were elevated despite suppressed NOS2 mRNA expression. Accompanied by the attenuated activity of arginase, the expression of arginase I at both the mRNA and protein level was downregulated. The levels of mRNA for T helper 2 cytokines such as IL-4, IL-5, and IL-13, and for chemotactants such as eotaxin-1 and eotaxin-2, were reduced. Moreover, the accumulation of inflammatory cells and the ratio of goblet cells in the bronchiole were decreased. The study concluded that the depletion of NO caused by arginase contributes to AHR and inflammation, and direct administration of an arginase inhibitor to the airway may be beneficial and could be of use in treating asthma due to its anti-inflammatory and airway-relaxing effects, although it is not clear whether the anti-inflammatory effect is direct or indirect.

KW - Arginase inhibitor

KW - Experimental asthma

KW - nor-NOHA

UR - http://www.scopus.com/inward/record.url?scp=77953522851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953522851&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00216.2009

DO - 10.1152/ajplung.00216.2009

M3 - Article

C2 - 20382750

AN - SCOPUS:77953522851

VL - 299

JO - American Journal of Physiology - Lung Cellular and Molecular Physiology

JF - American Journal of Physiology - Lung Cellular and Molecular Physiology

SN - 1040-0605

IS - 1

ER -